White Papers

Antibody-Drug-Conjugates (ADC) have emerged as an efficient technology to deliver cytotoxic drugs into cancerogenic cells. The mechanism is based on an antigen-mediated uptake of a cytotoxic drug conjugated antigen via clathrin-mediated endocytosis and release of the drug after lysosomal cleavage to its intracellular target. With 14 ADCs currently approved worldwide, ADCs have proven their therapeutic […]

The focus on drug discovery has been shifted from the traditional small molecules to biologics and new modalities as a result of increasing research to address unmet medical needs. This evolution requires drug delivery technologies capable of carrying the drug intact to specific sites in the body and across cellular membranes to reach their targets. […]

During the drug development process there are many critical milestones and many more potential pitfalls which could seriously impact the timely progression of a new compound into the next phase. One of the major milestones is the entry into clinical phase 1, where a new compound is administered to healthy subjects for the first time. […]

The drug development process, from drug discovery to the clinical proof of concept (PoC) is costly and high-risk. The high rewards of a successful development, both ethical and commercial, excites scientists, researchers, and investors . Starting from scientific endeavors, drug discovery is mainly driven by the pre-clinical pharmacology and toxicity as well as the fast […]

Although a technically challenging process, spray drying is a mature, well understood technique capable of transforming solutions or suspensions into solid particles. Although this process has been widely used in diverse industrial fields, it has become more and more demanded in pharmaceutical applications for the production of solid dispersions. Today’s APIs are increasingly insoluble and […]

The history of cannabis begins already in antiquity and its therapeutic use has been documented for 2700 years. In the year 1850, cannabis was included in the United States Pharmacopoeia (USP) before it was deleted in 1942, after a new legislation in 1937 classified cannabis as a narcotic and was subsequently prohibited. Since that time, […]

Engineered therapeutic proteins, monoclonal antibodies (MAbs) as well as bispecific monoclonal antibodies (BsMAbs), genes or genetic sequences (e.g. mRNAs, oligonucleotides), and cell and engineered cell based therapeutics (e.g. stem cell, CAR-T-cells) have demonstrated the successful delivery of breakthrough therapies for many unmet medical needs. The enthusiasm continues to increase the pipelines of the pharmaceutical industry […]